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Introduction: Three single-nucleotide polymorphisms in the calci-
um-sensing receptor gene (CASR) encoding the missense substitu-
tions A986S, R990G, and Q1011E have been associated with normal
variation in extracellular calcium homeostasis, both individually and
in haplotype combination. The aim of this study was to examine
haplotype associations in primary hyperparathyroidism (PHPT).
Patients andMethods:Patientswith sporadic PHPT (n 237)were
recruited from endocrine clinics and healthy controls (n  433) from
a blood donor clinic, and levels of serum calcium, albumin, and PTH
were measured. In PHPT patients, urinary calcium/creatinine clear-
ances and bone mineral density at spine and femoral neck were
measured and the presence of kidney stones and vertebral fractures
identified. The CASR single-nucleotide polymorphisms were haplo-
typed by allele-specific sequencing.
Results: Four haplotypes (ARQ, SRQ, AGQ, and ARE) of eight were
observed, in keepingwith significant linkage disequilibrium, but hap-
lotype frequencies did not show significant Hardy-Weinberg disequi-
librium. The SRQ haplotype was more common in PHPT (125 of 474
alleles) than in controls (170 of 866 alleles, P  0.006) and showed a
significant (P  0.006) gene-dosage effect. There was no significant
association between haplotype and bonemineral density or fractures,
but associationwith kidney stoneswas significant (P 0.0007). In the
stone-forming subgroup, the SRQ haplotype was underrepresented
and AGQ overrepresented. Patients bearing the AGQ haplotype had
an odds ratio of 3.8 (95% confidence interval, 1.30–11.3) for presen-
tation with renal stones compared with the rest.
Conclusion: Our data indicate that the CASR SRQ haplotype is
significantly associated with PHPT in our population. Within the
PHPT patient population, the AGQ haplotype is significantly asso-
ciated with kidney stones. (J Clin Endocrinol Metab 92: 277–283,
2007)
SERUM CALCIUM CONCENTRATIONS are under sig-nificant genetic control in normal individuals (1, 2) and
are maintained within a narrow range by PTH. The rela-
tionship between serum calcium and PTH levels is mediated
by the calcium-sensing receptor (CASR), a Gprotein-coupled
cell-surface glycoprotein expressed in parathyroid gland and
renal tubular cells (3). In the kidney, its activation induces
increased calcium excretion (3). Inactivating or activating
mutations of the CASR cause familial hypocalciuric hyper-
calcemia (FHH) or autosomal dominant hypocalcemia, re-
spectively (4, 5), emphasizing the central role of the CASR in
blood calcium homeostasis. Three single-nucleotide poly-
morphisms (SNPs) in exon 7 of the CASR gene (CASR), all
encoding nonconservative amino acid changes (A986S,
R990G, and Q1011E) and clustered in the CASR carboxyl-
terminal tail, have been described (6). These polymorphisms
have been found to be predictive of serum calcium concen-
trations in normal Caucasian populations either individually
(7, 8) or in haplotype combination (9).
Thus, the CASR is a candidate gene for association with
disorders of calcium regulation (7). Vezzoli et al. (10) found
that CASR R990G was associated with urinary calcium ex-
cretion in a population of Caucasian hypercalciuric stone
formers. Comparisons of normal individuals and patients
with primary hyperparathyroidism (PHPT), a common dis-
order of calcium homeostasis affecting 0.3% of the general
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population (11) and 2.1% of postmenopausal women (12),
that seek association with the CASR SNPs have been con-
ducted only on a small scale and without significant positive
findings (13, 14).
These observations prompted us to undertake a more de-
finitive study in a larger group of patients with sporadic
PHPT in comparison with healthy control subjects, looking
at the development of the disease and its sequelae, osteo-
porosis, fractures, and renal stones.
Subjects and Methods
Subjects
From April 2001 to December 2004, 312 patients with PHPT were
recruited at two referral centers, Rome and San Giovanni Rotondo. In
all patients, serum calcium, albumin, creatinine, PTH, prolactin, gastrin,
and calcitonin and urinary metanephrines, 5-hydroxy-indoleacetic acid,
and calcium/creatinine clearance ratio (calcium clearance) were mea-
sured. Criteria for exclusion from this study included hormonal and
biochemical results or a familial history suggestive ofmultiple endocrine
neoplasia types 1 or 2, FHH, or familial isolated hyperparathyroidism.
Patients with parathyroid carcinoma were likewise excluded. A total of
237 (Rome, 47, and San Giovanni Rotondo, 190) sporadic PHPT patients
were included: 41 males [aged 57 15 yr (mean sd)] and 196 females
[aged 58  13 yr (43 premenopausal, aged 40  10 yr, and 153 post-
menopausal, aged 63  8 yr)]. One hundred fifty-three subjects under-
went surgery for parathyroidectomy, and a histological diagnosis of
adenoma or hyperplasia was made in 127 and 26, respectively.
Control subjects were recruited from a blood donor clinic after ex-
clusion of those taking drugs or affected by diseases influencing bone
metabolism. In all, serum calcium, albumin, creatinine, and PTH were
measured. Subjects whose results were outside the normal reference
interval were excluded. The 433 control subjects remaining included 205
males [aged 38  10 yr (mean  sd)] and 228 females [aged 40  11 yr
(167 premenopausal, aged 35 9 yr, and 61 postmenopausal, aged 53
4 yr)].
All subjects gave informed consent for the study that was approved
by the ethical committees of Casa Sollievo della Sofferenza Hospital and
Roma University Department of Clinical Science.
Genetic analysis
Genomic DNAwas extracted from peripheral white blood cells using
standard techniques. A 282-bp fragment of CASR exon 7 was amplified
as before (9), and the three CASR SNPs were determined by direct
sequencing. For the doubly heterozygous subjects, phase was resolved
using allele-specific amplification at the first locus and heterozygosity
detection at the second, and the four observed haplotypes (ARQ, SRQ,
AGQ, and ARE) were assigned as described before (9).
Chemistries
Serum calcium, albumin, and creatinine and urinary calcium and
creatinine were measured by standard colorimetric techniques. Serum
intact PTH was measured by Allegro immunoradiometric assay (Ni-
chols Institute Diagnostics, San Juan Capistrano, CA) with intra- and
interassay coefficients of variation of 5.1 and 8.2%, respectively, and a
reference interval of 10–72 pg/ml.
Bone mineral density (BMD), fractures, and renal stones
BMD was measured by dual-energy x-ray absorptiometry (DXA)
(Hologic,Waltham,MA) at the spine (DXAL2-L4, in vivo precision 1.0%)
and femoral neck (in vivo precision 2.3%). Individual BMD values were
expressed as sd units (Z-values) in relation to age-matched reference
populations of each center (15). Conventional spinal radiographs in
lateral (T4–L4) and anteroposterior projection (L1–L4) were obtained
with a standardized technique. Vertebral fractures were diagnosed by
visual inspection using the semiquantitative method described by
Genant et al. (16). History of nonvertebral fractures was collected from
patient medical records.
Subjects with a presumptive diagnosis of PHPT were routinely as-
sessed for a history of renal stones, including renal ultrasound exami-
nation. Those who had renal colic also underwent urography and plain-
film radiography. Documentation of urographic and plain-film
radiographic results and surgical removal of stones was obtained by
review of medical records. Subjects were considered as stone formers if
1) they had a positive history for renal stones according to ultrasound
examination, urography, plain-film radiography, or surgical removal, as
recorded in the patient chart, or 2) renal stones were diagnosed by these
procedures in either asymptomatic and symptomatic patients at phys-
ical examination.
Statistical analysis
Linkage and Hardy-Weinberg disequilibria were assessed using the
Genetic Data Analysis program [Lewis, P. O., and D. Zaykin, computer
program for the analysis of allelic data (version 1.0d16c)] based on
standard methods described by Weir (17).
The 2 test was used for evaluating the association of tri-locus hap-
lotypes with disease and, within the PHPT group, with renal stone or
fracture phenotype. Differences among biochemical parameters both in
patients and in controls in relation to the tri-locus haplotypes were
performed by one-way ANOVA and Duncan post hoc comparisons or
Student’s t test for unpaired data, as appropriate. Excluded from the
associational analyses were the single instances of homozygosity at
R990G (AGQ/AGQ) and Q1011E (ARE/ARE) in the control group and
in the patient group, respectively, leaving 432 and 236 subjects in each
cohort. General linear modeling (GLM) was applied, both in the patient
group and in the control group, to evaluate the contribution of haplo-
types to serum calcium levels after correction for the following variables:
age, sex, serum creatinine, and serum PTH.
In the PHPT group, bivariate association between haplotypes (ex-
pressed as ordinal levels 0, 1, and 2, according to the number of CASR
haplotype alleles) and biochemical data were performed by Kendall’s
-b correlation. In the PHPT group, GLMwas performed to evaluate the
potential association between haplotypes and BMD measured at spine
and femoral neck after correction for the following variables: body mass
index (BMI, kg/m2), serum PTH, and calcium clearance.
Logistic regression analysis was performed to evaluate the influence
of the different haplotypes in predicting disease status in all subjects.
Moreover, in the PHPT group, it was used to evaluate the influence of
the different haplotypes in predicting the presence of renal stones after
correction for the following variables: age, sex, serum PTH, and calcium
clearance.
Unadjusted odds ratios (OR) for the presence of the 986S genotype in
PHPT cohorts and controls were calculated for this study and two other
published studies (13, 14) and then pooled using a random-effectsmodel
as described (18). A 95% confidence interval (CI) was calculated for the
summary OR using the same method. Heterogeneity across the studies
was assessed by visual inspection, and a formal statistical test was done
as described (19). The hypothesis that the studies were not heteroge-
neous was rejected at P  0.05.
Data are expressed as mean  se, unless otherwise indicated. A P
value of less than 0.05 was considered significant. All nongenetic anal-
yses were performed using the SPSS version 12.0 statistical package
(SPSS Inc., Chicago, IL).
Results
As expected, linkage disequilibrium was observed for all
three pairwise comparisons between the three clusteredmis-
sense polymorphisms. However, haplotype distributions
within genotypes showed no significant departure fromHar-
dy-Weinberg equilibrium in PHPT patients or controls.
The tri-locus haplotype frequencies for the CASR were
significantly different between PHPT and control groups
(2 8.39; P 0.038), withmost of the difference attributable
to the SRQ haplotype (Table 1). Analysis of SRQ haplotype
alone revealed a significantly higher frequency in PHPT pa-
tients than in controls (2 7.72; P 0.006) and a significant
trend for SRQ with disease status (2  7.58; P  0.006).
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After adjustment for the other covariates, serum calcium
(albumin-adjusted, Caalb-adj) was significantly and positively
associated with SRQ (P  0.0001) in controls and negatively
with AGQ (P  0.026) (Table 2). In the control group, there
was a significant trend for Caalb-adj with SRQ (F for trend 
21.6; P  0.0001) but not in the patient group (Table 2). Age,
serum creatinine, and PTH were not different in either con-
trols or patients stratified by haplotype (Table 2).
Bivariate correlation between haplotypes and key bio-
chemical parameters in the PHPT group (Table 3) showed
that SRQ was significantly and negatively associated with
calcium clearance (r  0.199; P  0.0001), whereas AGQ
was significantly and positively associated (r  0.140; P 
0.013). No significant correlations were seen with serum cre-
atinine or PTH.
When stratified by haplotype, no significant differences
were seen for BMD, whether measured at lumbar spine or
femoral neck, or for fractures (Table 4).
In an analysis of the PHPT cohort alone (Table 5), the
kidney stone phenotype revealed significant association
with haplotype (2 17.2;P 0.0007). The SRQhaplotypewas
significantly and negatively associated with stone-former sta-
tus, and a significant trend for SRQ vs. non-stone phenotype (2
 6.25; P 0.012) was observed, whereas the AGQ haplotype
was significantly and positively associated with the stone phe-
notype (Table 5).
Comparison of PHPT patients with and without kidney
stones is summarized in Table 6. Patients with stones were
somewhat younger, more likely to be male, and had higher
serum PTH and urinary calcium indices, but serum calcium
was higher in stone-formers. Logistic regression analysis
showed that the CASR AGQ haplotype was positively as-
sociatedwith renal stones (P 0.015) after correction for age,
sex, serum PTH, and calcium clearance. Overall, PHPT sub-
jects with AGQ had a 3.8-fold higher risk of developing renal
stones (95% CI, 1.30–11.3) (Fig. 1). In the regression model,
covariates significantly associated with stone phenotype
were age (P  0.028) and calcium clearance (P  0.031).
Moreover, logistic regression analysis showed that the CASR
AGQ haplotype was positively associated with renal stones
(P  0.010) after correction for age, sex, serum PTH, and
serum calcium.
TABLE 1. Individual haplotype frequencies in PHPT and control groups
CASR haplotype frequency (%)
ARQ SRQ AGQ ARE
PHPTa 316/474 (66.7) 125/474 (26.4)b 19/474 (4.0) 14/474 (3.0)
Control 623/866 (71.9) 170/866 (19.6) 43/866 (5.0) 30/866 (3.5)
a Significantly different: P  0.039 for 2  8.39 by contingency table analysis with three degrees of freedom.
b Significantly greater than in controls: P  0.006 for 2  7.72 with one degree of freedom.
TABLE 2. Clinical characteristics according to tri-locus haplotype
Allele Haplotype
Clinical data
No. of subjects Sex (male/female) Age (yr) Caalb-adj (mg/dl) PTH (pg/ml) Creatinine (mg/dl)
PHPT patients
ARQ X/X 27 2/25 61  2 11.12  0.17 133  16 0.95  0.05
X/ARQ 102 19/83 57  1 11.14  0.08 170  15 0.91  0.02
ARQ/ARQ 107 20/87 58  1 11.15  0.08 187  18 0.96  0.03
SRQ X/X 133 26/107 58  1 11.20  0.07 192  17 0.97  0.03
X/SRQ 81 13/68 57  2 11.04  0.10 152  12 0.88  0.02
SRQ/SRQ 22 2/20 60  3 11.17  0.18 140  20 0.93  0.05
AGQ X/X 217 37/180 58  1 11.12  0.06 168  11 0.93  0.02
X/AGQ 19 4/15 58  3 11.35  0.19 234  59 1.05  0.08
ARE X/X 224 39/185 58  1 11.14  0.06 176  11 0.94  0.02
X/ARE 12 2/10 59  3 11.27  0.25 134  20 0.96  0.07
Controls
ARQ X/Xc 29 11/18 39  2 9.37  0.05a 37  3 0.82  0.03
X/ARQ 183 82/101 40  1 9.23  0.02 41  1 0.83  0.01
ARQ/ARQ 220 111/109 38  1 9.17  0.02 40  1 0.83  0.01
SRQ X/X 282 138/144 39  1 9.17  0.02 40  1 0.83  0.01
X/SRQ 130 58/72 40  1 9.26  0.03b 41  1 0.82  0.01
SRQ/SRQ 20 8/12 37  3 9.46  0.07c,d 38  4 0.84  0.04
AGQ X/X 391 188/203 39  1 9.22  0.02e 40  1 0.82  0.01
X/AGQ 41 16/25 42  2 9.11  0.05 39  2 0.86  0.02
ARE X/X 402 190/212 39  1 9.21  0.02 40  1 0.83  0.01
X/ARE 30 14/16 41  2 9.25  0.05 44  3 0.81  0.03
Data are shown as mean  SE. Data were analyzed by one-way ANOVA and Duncan post hoc comparison or t test for unpaired data, as
appropriate. Caalb-adj was evaluated by GLMafter correction for age, sex, serum creatinine, and PTH and Sidak post hoc comparison. X indicates
any other haplotype.
a P  0.001 for X/X vs. X/ARQ and ARQ/ARQ.
b P  0.007 for X/SRQ vs. X/X.
c P  0.0001 for SRQ/SRQ vs. X/X.
d P  0.015 for SRQ/SRQ vs. X/SRQ.
e P  0.026 for X/X vs. X/AGQ.
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Discussion
PHPT is characterized by dysregulated PTH secretion and
parathyroid cell growth (20). The pivotal role of the para-
thyroid CASR in orchestrating calcium homeostasis and reg-
ulating parathyroid secretory function and cell proliferation
is emphasized by the clinical phenotypes of humans with
CASR-inactivatingmutations (4).Heterozygous loss-of-func-
tion mutations give rise to FHH in which the lifelong hy-
percalcemia is typically asymptomatic (21). Although overt
hyperparathyroidism is not normally a part of this benign
phenotype, members of some FHH kindreds (or in some
cases those classified as having familial isolated hyperpara-
thyroidism) present atypically with hyperparathyroidism,
and surgical removal of the adenoma or hyperplastic glands
can be curative (22–26). The homozygous condition mani-
fests as neonatal severe hyperparathyroidism characterized
by marked parathyroid hypercellularity (21).
Mouse models of FHH and neonatal severe hyperpara-
thyroidism have been generated by heterozygous or ho-
mozygous deletions, respectively, of the Casr gene (27). The
homozygous null mutants die shortly after birth with severe
hypercalcemia and hyperparathyroidism. However, genetic
ablation of PTH is sufficient to rescue the lethal Casr/
phenotype (28). Adult Pth/, Casr/ mice exhibit an ex-
panded range of serum and urine calcium values, highlight-
ing the importance of the CASR in fine control of blood
calcium levels and renal calcium excretion, even in the ab-
sence of PTH (28).
The Pth/Casr/ double knockouts have markedly en-
larged parathyroid glands, confirming the importance of
normal serum calcium concentrations and CASR in the in-
hibition of parathyroid cell proliferation (20). Whether ab-
normal parathyroid proliferation in PHPT is always the re-
sult of alteration in calcium-regulated PTH secretion has
been the subject of some debate (29). In a transgenic mouse
model of primary hyperparathyroidism in which the cyclin
D1 protooncogene is targeted to parathyroid cells (30), ab-
normal parathyroid proliferation precedes dysregulation of
the calcium-PTH axis (31). In this particular model, then, it
could be concluded that the proliferative defect need not
occur as a consequence of the defective coupling of secretory
control of PTH to serum calcium. Although overexpression
of cyclin D1 occurs in 20–40% of PHPT tumors, no differ-
ences were found between PHPT and control groups in the
allele frequency of an NciI polymorphism in the cyclin D1
gene (32). It is likely that the mechanisms underlying the
development and progression of primary parathyroid tu-
mors are heterogeneous, and no single mechanism predom-
inates (33).
In healthy adult Caucasian populations, the association of
the A986S polymorphism in the CASR carboxyl-terminal tail
with normal variation in extracellular calcium concentration,
both individually (7, 8) and in haplotype combination with
the neighboring R990G andQ1011E polymorphisms (9), sug-
gests that CASR is a good candidate for association studies
in PHPT populations. Nevertheless, CASR A986S, the most
common polymorphic variant in Caucasians, was not found
to be significantly associated with PHPT in two earlier stud-
ies, albeit with smaller numbers of subjects (13, 14). Never-
theless, a trend toward a higher frequency of the 986S variant
(ASSS vs. AA-wild-type) in PHPT is evident in those data
sets [in Miedlich et al. (13), 20 of 50 patients (40%) vs. 29 of
102 controls (29%); in Cetani et al. (14), 41 of 103 (40%)
patients vs. 45 of 148 controls (30%)]. Those frequencies are
comparable to our study [103 of 237 patients (43.5%) vs. 150
of 433 controls (34.6%)]. It is not surprising that metaanalysis
of the pooled data are clearly consistent with association
between A986S and PHPT status (P  0.002), the pooled OR
being 1.49 (95% CI, 1.15–1.93) (see Fig. 2).
TABLE 3. Bivariate correlation analysis in the PHPT cohort
Clinical data
Allele
ARQ SRQ AGQ ARE
Caalb-adj (mg/dl) 0.053 0.102 0.063 0.041
Creatinine (mg/dl) 0.028 0.065 0.091 0.021
PTH (pg/ml) 0.051 0.080 0.079 0.025
Cau/Cru (mg/mg) 0.037 0.082 0.052 0.050
Calcium excretion 0.075 0.138a 0.088 0.052
Calcium clearance 0.120b 0.199c 0.140d 0.022
Datawere assessed byKendall’s  -b correlation. Calcium excretion
was calculated as urinary calcium (Cau)/urinary creatinine (Cru) 
serum creatinine (mmol/liter glomerular filtrate).
a P  0.010.
b P  0.028.
c P  0.0001.
d P  0.013.
TABLE 4. BMD (Z-DXA at spine and femoral neck) and fractures according to haplotype
Allele Haplotype
Clinical data
n Total Fx (y/n) Z-(L2–L4) Z-FN
ARQ X/X 24 8/16 0.075  0.334 0.258  0.243
X/ARQ 91 38/53 0.634  0.174 0.542  0.130
ARQ/ARQ 102 36/66 0.550  0.157 0.485  0.117
SRQ X/X 125 46/79 0.518  0.145 0.459  0.109
X/SRQ 71 28/43 0.643  0.199 0.556  0.146
SRQ/SRQ 21 8/13 0.254  0.352 0.371  0.256
AGQ X/X 200 74/126 0.547  0.114 0.498  0.084
X/AGQ 17 8/9 0.298  0.425 0.213  0.337
ARE X/X 208 80/128 0.552  0.112 0.493  0.082
X/ARE 9 2/7 0.050  0.561 0.127  0.439
Data are presented as mean  SE. The total number (n) of PHPT patients was 217 (91.6% of patients enrolled) after exclusion of those on
medications or affected by diseases that influence bone metabolism. X indicates any other haplotype. Z-values were analyzed by GLM after
correction for BMI, PTH, and calcium/creatinine clearance ratio. FN, Femoral neck; Fx, fractures; y/n, yes/no.
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In our previous study of a large cohort of Caucasian sub-
jects (9), the tri-locus SNP cluster (A986S, R990G, and
Q1011E) was a significant predictor of blood ionized calcium
levels. Subjects with SRQ and ARE haplotypes were rela-
tively hypercalcemic, whereas those with AGQ were hy-
pocalcemic, relative to subjects with the wild-type ARQ hap-
lotype. In the present study, although the association of
serum calcium with haplotype we have observed before is
also evident in our controls, it is not seen in the patient group.
We suggest that the tri-locus haplotypes, if they are func-
tionally important in the normal homeostasis of serum cal-
cium, become less so once inhibition of parathyroid cell pro-
liferation and differentiation is lost in PHPT.
In the present study, we found that the SRQ haplotype is
significantlymore common in PHPTpatients than in controls
and shows a significant gene dosage effect with disease sta-
tus. Furthermore, in PHPT stone formers, the lower fre-
quency of SRQ and the higher frequency of AGQ, together
with the significant association of SRQ (negatively) andAGQ
(positively) with calcium clearance, supports a counterbal-
ancing function of these polymorphic variants, the 986S be-
ing relatively inactivating and the 990G activating relative to
wild-type ARQ. The association of higher serum calcium in
healthy subjects bearing the SRQhaplotype and lower serum
calcium in healthy subjects bearing the AGQ haplotype ar-
gues for a functional role for these polymorphic variants.
This hypothesis is in keepingwith the observation byVezzoli
et al. (10) of a higher frequency of 990G variant in hypercal-
ciuric stone formers than normocalciuric ones or controls.
The same investigators recently presented preliminary data
demonstrating that polymorphic variant 990G of the CASR
gene results in CASR gain-of-function, which should result
in greater inhibition of calcium reabsorption in distal tubular
cells of the kidney and cause hypercalciuria (34).
In our PHPT patients, logistic regression analysis showed
that subjects bearing the AGQ haplotype have a 3.8-fold
higher risk of developing renal stones after correcting for
covariates. In PHPT subjects, we calculated calcium clear-
ances as a measure of calcium excretion, taking into account
FIG. 1. Relative haplotype frequencies in the PHPT cohort stratified
by the presence (black bar) or absence (gray bar) of renal stones. The
error bar represents the 95% CI for the proportion. The difference in
the distribution of frequencies of all four haplotypes was significant
(2  17.2; P  0.0007); *, P  0.05, presence vs. absence of renal
stones for SRQ and AGQ groups.
TABLE 5. Frequency of a positive kidney stone phenotype according to haplotype
Allele Haplotype
Clinical data
n Sex
(male/female)
Age
(yr)
Kidney stones
(y/n)
PTH
(pg/ml)
Calcium excretiond
(mmol/liter GF)
Calcium
clearance
ARQ X/X 24 1/23 60  3 10/14 138  18 0.065  0.008 0.023  0.002
X/ARQ 96 19/77 57  1 54/42 174  16 0.070  0.05 0.024  0.001
ARQ/ARQ 105 20/85 58  1 57/48 188  19 0.073  0.003 0.026  0.001
SRQ X/X 130 26/104 58  1 78/52a 194  18 0.078  0.005 0.027  0.001b
X/SRQ 74 13/61 57  2 36/38 156  14 0.063  0.005 0.021  0.001
SRQ/SRQ 21 1/20 60  3 7/14 142  20 0.065  0.008 0.023  0.003
AGQ X/X 207 36/171 58  1 105/102 171  11 0.070  0.003 0.024  0.001
X/AGQ 18 4/14 57  3 16/2e 242  62 0.093  0.015c 0.032  0.004d
ARE X/X 215 38/177 58  1 113/102 179  12 0.070  0.003 0.025  0.001
X/ARE 10 2/8 59  5 8/2 138  24 0.080  0.013 0.026  0.004
Data are shown asmean SE. Total number (n) of PHPT patients was 225 (94.9% of patients enrolled) after exclusion of those onmedications
or affected by diseases that influence kidney stone formation. X indicates any other haplotype. Calcium excretion was calculated as (urinary
calcium/urinary creatinine)  serum creatinine. GF, Glomerular filtrate; y/n, yes/no.
a 2  6.34; P  0.042 for X/X vs. SRQ/SRQ.
b P  0.003 for X/X vs. X/SRQ, by one-way ANOVA and Duncan post hoc comparison.
c P  0.017 for X/AGQ vs. X/X, by t test for unpaired data.
d P  0.005 for X/AGQ vs. X/X, by t test for unpaired data.
e By Fisher exact test  9.70; P  0.002 for X/AGQ vs. X/X.
TABLE 6. Clinical characteristics of PHPT patients with and
without stones
Clinical data
Kidney stone
Yes No
Sex (male/female) 25/96 15/89
Age (yr) 55  1.24 61  1.19a
Caalb-adj (mg/dl) 11.37  0.10
b 10.96  0.08
PTH (pg/ml) 183  14.9 169  17.4
Creatinine (mg/dl) 0.98  0.03c 0.88  0.02
GFR (ml/min) 72.2  1.7 70.7  1.8
Cau/Cru (mg/mg) 0.33  0.02 0.29  0.02
Calcium excretion (mmol/liter GF) 0.078  0.005d 0.063  0.003
Calcium clearance 0.027  0.001c 0.022  0.001
Data are shown as mean  SE. Differences were analyzed by t test
for unpaired data. Glomerular filtration rate (GFR) was calculated
according to the Cockroft-Gault equation by GLM analysis after ad-
justing for age. Calcium excretion was calculated as urinary calcium
(Cau)/urinary creatinine (Cru)  serum creatinine. GF, Glomerular
filtrate.
a P  0.001.
b P  0.002.
c P  0.003.
d P  0.005.
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both renal function and serum calcium levels. Correlation
between AGQ haplotype and clearance suggest that predis-
position to development of renal stones could be a result of
increased calcium clearance, but whether it is exclusively
mediated by a decreased inhibitory effect of the AGQ-con-
taining CASR on suppression of renal calcium reabsorption
with subsequent hypercalciuria cannot be assessed from our
data, especially given the ascertainment bias introduced by
selection of cohorts from PHPT populations presenting at
hospital clinics. However, the significant association of AGQ
with stones after adjustment for calcium clearance suggests
the possibility of AGQ-mediated actions that are indepen-
dent of the effect on hypercalciuria.
Although the CASR is involved in bone metabolism either
directly through osteoclast activity (35, 36) or indirectly
through its effect on regulation of PTH secretion and calcium
metabolism (3), the reports of association between measures
of bone quality (DXA and heel ultrasound) and the CASR
haplotype variants have been inconsistent (37–40). In a study
of 230 Hungarian postmenopausal women, CASR 986S was
not significantly associated with BMD (41) or with vertebral
fractures in 219 Italian postmenopausal women (42). Like-
wise, in the present study,wedid not observe any association
between CASR haplotype and bone mass by DXA or with
fractures.
In conclusion, the data show a significant association of
SRQ haplotype in PHPT patients, thus suggesting it as a
susceptibility marker for the development of PHPT. More-
over, this is the first evidence that PHPT patients bearing the
AGQ haplotype are at greater risk, whereas those having the
SRQ haplotype are at lesser risk, of developing renal stones.
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